A new meta-analysis shows that psychiatric medications can give some protection against COVID-19, with the common antidepressant fluvoxamine showing the strongest effect. Patients taking fluvoxamine showed reduced symptoms, with the analysis indicating that mortality was around 15% lower than in those not taking fluvoxamine. 온라인카지노
The analysis considered 30 clinical studies, including 145,000 patients. The resulting paper, “Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis,” will be published in the January 2023 edition of the journal European Neuropsychopharmacology. Here is a brief interview between the ECNP Press Officer, Tom Parkhill, and the lead author, Dr. Giovanna Fico (University of Barcelona): GF: We found that fluvoxamine may reduce the risk of severe COVID-19 outcomes and might be a good candidate for drug repurposing in COVID-19, while the increased risk for severe COVID-19 with antipsychotics is not absolute and depends on individual cases. 바카라
GF: Evidence on the efficacy of antidepressants for the treatment of COVID-19 is still scarce, so we cannot conclude that clinicians should start antidepressants in patients with COVID-19 infection. However, patients already on treatment with antidepressants who get infected with COVID-19, should not discontinue this treatment. There are a couple of reasons for this. First, patients with depressive disorder who discontinue antidepressants have a higher risk of having another depressive episode. Second, we know that antidepressants can be prescribed safely in patients with COVID-19. We believe it is possible that antidepressants can reduce mortality in patients with COVID-19, but the evidence is still weak. 온라인바카라
GF: Several randomized clinical trials on fluvoxamine as COVID-19 treatment have been conducted (also after the publication of our meta-analysis). The last published paper on RCT on the topic stated, “Based on our reanalysis, it appears fluvoxamine is associated with a statistically significant decrease in the risk of hospitalization when given to COVID-19 outpatients.” Still, I believe, we have too little evidence to make clinical recommendations to start fluvoxamine in patients at risk for severe COVID-19. 안전놀이터
Experimental Compound Shown To Block Effects Of Multiple Harmful Drugs
When someone overdoses on opioid drugs, a medication called naloxone can save their life by quickly mitigating the effects of the narcotics. A new chemical shows promise for serving a similar role, but it also works on non-opioid drugs.